More Than 200 New Drugs Developed By International Players Encounter Approval Delays in Turkey
This article was originally published in PharmAsia News
Executive Summary
A major grouping of pharmaceutical makers in Turkey said that a new government rule requiring separate good manufacturing practice certification from the Ministry of Health has delayed approval for 287 new drugs manufactured by international firms
You may also be interested in...
Lilly Among MNCs Scouting In Turkey For Local Partners As GMP Inspection Backlog Continues
Eli Lilly & Co. Inc. has been rumored to be in partnership talks with Turkish Mustafa Nevzat Pharmaceuticals. The U.S. drug maker is reportedly looking for a minority stake in the Turkish generics maker
Lilly Among MNCs Scouting In Turkey For Local Partners As GMP Inspection Backlog Continues
Eli Lilly & Co. Inc. has been rumored to be in partnership talks with Turkish Mustafa Nevzat Pharmaceuticals. The U.S. drug maker is reportedly looking for a minority stake in the Turkish generics maker
GSK Reportedly Bidding For Turkish Biofarma, Local Manufacturing Key To Market Registration
GlaxoSmithKline PLC is rumored to be among three final bidders for Turkish generic drug maker Biofarma Pharmaceutical Industry Co. Inc. MNCs in Turkey are stepping up plans to establish a local manufacturing presence in Turkey to respond to continued price pressure, according to analysts